Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 26, 2019Clinical CardiologyOpen Access

HFpEF remains a complex systemic geriatric syndrome lacking universally accepted disease-modifying therapies.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Understanding of HFpEF pathophysiology remains incomplete, drug development has been challenging, and no universally accepted therapies alter its clinical course.

Design

Review

Key result

Heart failure with preserved ejection fraction is a complex, systemic geriatric syndrome involving multiple organ systems, for which there are currently no universally accepted disease-modifying therapies.

Authors

BUBharathi UpadhyaDKDalane W. Kitzman

Discussion

Loading...

Member takes

Overview

Shifts HFpEF care toward holistic geriatric assessment; leaves open targeted disease-modifying therapies.

Structured PICO

P
Population
Patients with heart failure with preserved ejection fraction (HFpEF)

This review highlights the paradigm shift in understanding HFpEF from an isolated diastolic dysfunction to a complex, systemic geriatric syndrome, emphasizing the need for novel therapeutic approaches.

Cite This Study

Upadhya et al. (2019) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Heart failure with preserved ejection fraction is a complex, systemic geriatric syndrome involving multiple organ systems, for which there are currently no universally accepted disease-modifying therapies.

synapsesocial.com/papers/6a0879da113ba5b476de344ehttps://doi.org/10.1002/clc.23321
View Full Paper
Ask AI
Bookmark
Share